RJFSA
TRIL

Raymond James Financial Services Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,581
Closed -$146K – 3416
2021
Q1 		$146K Buy
13,581
+2,781
+26% +$34.4K ﹤0.01% 2988
2020
Q4 		$159K Sell
10,800
-2,500
-19% -$36.1K ﹤0.01% 2780
2020
Q3 		$189K Buy
13,300
+1,500
+13% +$15K ﹤0.01% 2561
2020
Q2 		$95K Buy
+11,800
New +$73K ﹤0.01% 2652

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Raymond James Financial Services Advisors's TRIL Position: Q2 2021 in Review

Raymond James Financial Services Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2021, closing a stake of 13,581 shares — an estimated $146K sold.

Raymond James Financial Services Advisors first reported a position in TRIL in Q2 2020 and held it in 4 quarters. The position peaked at $189K in Q3 2020. 137 funds tracked by Wall St. Rank hold TRIL as of Q2 2021.

  • Raymond James Financial Services Advisors reported no remaining Trillium Therapeutics Inc. position as of Q2 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 13,581 Trillium Therapeutics Inc. shares in Q2 2021, an estimated $146K.
  • Raymond James Financial Services Advisors first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 4 quarters.
  • Raymond James Financial Services Advisors's Trillium Therapeutics Inc. position peaked at $189K in Q3 2020.
  • 137 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.